drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Anti-GD2 IgG1 monoclonal antibody immunotherapy that binds GD2 on neuroblastoma cells and mediates Fc-dependent ADCC, ADCP, and CDC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
naxitamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-GD2 IgG1 monoclonal antibody that binds GD2 on neuroblastoma cells and triggers Fc-mediated effector functions—ADCC by NK cells, ADCP by macrophages—and complement-dependent cytotoxicity (CDC), leading to tumor cell lysis.
drug_name
Naxitamab (DANYELZA)
nct_id_drug_ref
NCT06574698